Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cefadroxil monohydrate

Executive Summary

Bristol-Myers Squibb patent is valid, the International Trade Commission concludes in a final determination March 15. The commission determined that the valid patent rendered illegal the importation of the product by generic competitors Biocraft and Purepac. Cease and desist orders were issued against the generic companies prohibiting domestic marketing of the antibiotic; a limited exclusion order prohibiting importation was issued against foreign firms GEMA, Istituto Biochimico Italiano Industria Giovanni Lorenzini and Institut Biochimique. Bond for all the companies included in both orders has been set at 68% of the entered value of the imported articles during a 60-day Presidential review period. If the final determination is not rejected, the orders hold until the patent expires in 2002, or an appeal. The cease and desist orders corroborate temporary orders in place since Jan. 10 ("The Pink Sheet" Jan. 22, "In Brief").

You may also be interested in...



The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

UsernamePublicRestriction

Register

PS017110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel